Xtant Medical (XTNT) Q2 FY26 earnings call

Xtant Medical reported a challenging Q2 FY26 with reduced revenue and profitability, primarily due to the cessation of license revenue, headwinds in the Amnio product line, and the temporary impact of integrating the Dilon sales force. Despite a modest reduction in full-year revenue guidance, the company is optimistic about future growth driven by its expanded commercial presence and new product launches like Trivium Shaped and HEMOBLAST, which are expected to drive sequential biologics growth in the second half of the year.